View in EDS PDF Full Text

A novel defined TLR3 agonist as an effective vaccine adjuvant.

Saved in:
Bibliographic Details
Title: A novel defined TLR3 agonist as an effective vaccine adjuvant.
Authors: Ko KH; Research and Development Center, NA Vaccine Institute, Seoul, Republic of Korea.; Interdisciplinary Program in Genetic Engineering, College of Natural Sciences, Seoul National University, Seoul, Republic of Korea., Cha SB; Research and Development Center, NA Vaccine Institute, Seoul, Republic of Korea., Lee SH; Research and Development Center, NA Vaccine Institute, Seoul, Republic of Korea., Bae HS; Research and Development Center, NA Vaccine Institute, Seoul, Republic of Korea., Ham CS; Research and Development Center, NA Vaccine Institute, Seoul, Republic of Korea., Lee MG; Research and Development Center, NA Vaccine Institute, Seoul, Republic of Korea., Kim DH; Research and Development Center, NA Vaccine Institute, Seoul, Republic of Korea., Han SH; Interdisciplinary Program in Genetic Engineering, College of Natural Sciences, Seoul National University, Seoul, Republic of Korea.; Department of Oral Microbiology and Immunology, and Dental Research Institute, School of Dentistry, Seoul National University, Seoul, Republic of Korea.
Source: Frontiers in immunology [Front Immunol] 2023 Jan 24; Vol. 14, pp. 1075291. Date of Electronic Publication: 2023 Jan 24 (Print Publication: 2023).
Publication Type: Journal Article; Research Support, Non-U.S. Gov't
Journal Info: Publisher: Frontiers Research Foundation] Country of Publication: Switzerland NLM ID: 101560960 Publication Model: eCollection Cited Medium: Internet ISSN: 1664-3224 (Electronic) Linking ISSN: 16643224 NLM ISO Abbreviation: Front Immunol Subsets: MEDLINE
Database: MEDLINE Ultimate
FullText Links:
  – Type: pdflink
Text:
  Availability: 0
Header DbId: mdl
DbLabel: MEDLINE Ultimate
An: 36761735
AccessLevel: 2
PubType: Academic Journal
PubTypeId: academicJournal
PreciseRelevancyScore: 0
IllustrationInfo
Items – Name: Title
  Label: Title
  Group: Ti
  Data: A novel defined TLR3 agonist as an effective vaccine adjuvant.
– Name: Author
  Label: Authors
  Group: Au
  Data: <searchLink fieldCode="AU" term="%22Ko+KH%22">Ko KH</searchLink>; Research and Development Center, NA Vaccine Institute, Seoul, Republic of Korea.; Interdisciplinary Program in Genetic Engineering, College of Natural Sciences, Seoul National University, Seoul, Republic of Korea.<br /><searchLink fieldCode="AU" term="%22Cha+SB%22">Cha SB</searchLink>; Research and Development Center, NA Vaccine Institute, Seoul, Republic of Korea.<br /><searchLink fieldCode="AU" term="%22Lee+SH%22">Lee SH</searchLink>; Research and Development Center, NA Vaccine Institute, Seoul, Republic of Korea.<br /><searchLink fieldCode="AU" term="%22Bae+HS%22">Bae HS</searchLink>; Research and Development Center, NA Vaccine Institute, Seoul, Republic of Korea.<br /><searchLink fieldCode="AU" term="%22Ham+CS%22">Ham CS</searchLink>; Research and Development Center, NA Vaccine Institute, Seoul, Republic of Korea.<br /><searchLink fieldCode="AU" term="%22Lee+MG%22">Lee MG</searchLink>; Research and Development Center, NA Vaccine Institute, Seoul, Republic of Korea.<br /><searchLink fieldCode="AU" term="%22Kim+DH%22">Kim DH</searchLink>; Research and Development Center, NA Vaccine Institute, Seoul, Republic of Korea.<br /><searchLink fieldCode="AU" term="%22Han+SH%22">Han SH</searchLink>; Interdisciplinary Program in Genetic Engineering, College of Natural Sciences, Seoul National University, Seoul, Republic of Korea.; Department of Oral Microbiology and Immunology, and Dental Research Institute, School of Dentistry, Seoul National University, Seoul, Republic of Korea.
– Name: TitleSource
  Label: Source
  Group: Src
  Data: <searchLink fieldCode="JN" term="%22101560960%22">Frontiers in immunology</searchLink> [Front Immunol] 2023 Jan 24; Vol. 14, pp. 1075291. <i>Date of Electronic Publication: </i>2023 Jan 24 (<i>Print Publication: </i>2023).
– Name: TypePub
  Label: Publication Type
  Group: TypPub
  Data: Journal Article; Research Support, Non-U.S. Gov't
– Name: TitleSource
  Label: Journal Info
  Group: Src
  Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22Frontiers+Research+Foundation]%22">Frontiers Research Foundation] </searchLink><i>Country of Publication: </i>Switzerland <i>NLM ID: </i>101560960 <i>Publication Model: </i>eCollection <i>Cited Medium: </i>Internet <i>ISSN: </i>1664-3224 (Electronic) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%2216643224%22">16643224 </searchLink><i>NLM ISO Abbreviation: </i>Front Immunol <i>Subsets: </i>MEDLINE
PLink https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=36761735
RecordInfo BibRecord:
  BibEntity:
    Identifiers:
      – Type: doi
        Value: 10.3389/fimmu.2023.1075291
    Languages:
      – Code: eng
        Text: English
    PhysicalDescription:
      Pagination:
        StartPage: 1075291
    Titles:
      – TitleFull: A novel defined TLR3 agonist as an effective vaccine adjuvant.
        Type: main
  BibRelationships:
    HasContributorRelationships:
      – PersonEntity:
          Name:
            NameFull: Ko KH
      – PersonEntity:
          Name:
            NameFull: Cha SB
      – PersonEntity:
          Name:
            NameFull: Lee SH
      – PersonEntity:
          Name:
            NameFull: Bae HS
      – PersonEntity:
          Name:
            NameFull: Ham CS
      – PersonEntity:
          Name:
            NameFull: Lee MG
      – PersonEntity:
          Name:
            NameFull: Kim DH
      – PersonEntity:
          Name:
            NameFull: Han SH
    IsPartOfRelationships:
      – BibEntity:
          Dates:
            – D: 24
              M: 01
              Text: 2023 Jan 24
              Type: published
              Y: 2023
          Identifiers:
            – Type: issn-electronic
              Value: 1664-3224
          Numbering:
            – Type: volume
              Value: 14
          Titles:
            – TitleFull: Frontiers in immunology
              Type: main
ResultId 1